CNS Leaders Forum: Agenda

Download the Agenda

Conference Day 1

  • Tuesday, June 15th
Tuesday, June 15th
8:00am ET

Conference Platform Opens

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels, and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

9:00am ET

Chair’s Opening Remarks and Setting the Scene

Magdalene Moran, President & Chief Scientific Officer, Caraway Therapeutics

 

9:05am ET

Keynote Presentation: What does the Future Looks Like for Patients with CNS Disorders?

  • What are the current efforts for treatment of CNS disorders?
  • What key challenges are we facing as an industry that is stalling progress?
  • How can we work together within the Neuroscience industry to advance patient treatment on the front line?

Innes Meldrum, SVP & Chief Commercial Officer,  Otsuka Pharmaceutical North America

9:30am ET

Wellness Break

9:35am ET

Panel Discussion: How Much is our Understanding of the Fundamental Biology Impacting the CNS Treatment?

  • How are therapeutic development efforts being limited by our understanding of the fundamental biology of the central nervous system?
  • What are some specific gaps within our knowledge that is preventing us from discovering more about CNS Diseases?
  • How can we implement new technology, such as AI or ML, to aid in CNS research?
  • What changes need to be made in clinical trials to help streamline efforts towards more effective results?
  • Where do we hope the research is in 5 years time?

Adele Diamond, Canada Research Chair Tier 1, Professor of Developmental Cognitive Neuroscience, The University of British Columbia

Newton Howard, Professor of Computational Neuroscience & Neurosurgery, Nuffield Department of Scientific Surgery, University of Oxford

Tiago Fleming Outeiro, Director of the Department of Experimental Neurodegeneration, University Medical Center Gottingen

Ray Dorsey, Professor of Neurology, Director, CHET, University of Rochester Medical Center

Natasha Hussein, Scientific Director, Kavli Neuroscience Discovery Institute, John Hopkins University & School of Medicine 

10:20am ET

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-ups throughout the rest of the event. 

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

10:50am ET

Presentation: Next-Gen Solutions for Neuroscience Problems 

  • A inside look at Genentech’s current neuroscience program
  • How are Genentech bringing tech to biotech to tackle CNS disorders?
  • How can you implement tech to modulate the most complex organ in the body?

Mikael Eliasson, Global Head of Innovation, Neuroscience, Genentech

11:15am ET

Wellness Break

11:20am ET

Presentation: Developing Cutting-Edge Medical Technology for Neuroscience Innovation

  • An insight into leading Medtech efforts for Neuro advancements
  • Will neuro-technology be readily available over the next 5 years?
  • What does the future hold for medtech in CNS?

Ryan Field, Chief Technology Officer, Kernel

11:45am ET

Wellness Break

11:50am ET

Panel Discussion: What Needs to Happen to Kickstart the Resurgence of Pharma back into CNS for Increased Patient Care?

  • What caused pharma to withdraw from CNS therapeutic development and what’s changed since then?
  • Where have we seen success with pharmaceutical companies in CNS?
  • What commercial strategy adaptations can be made to ensure there is an ROI in such an uncertain field?
  • Can the utilization of digital health tech take traditional pharma to the frontline for CNS therapeutic R&D? 
  • Are we likely to see partnerships with pharma, Biotechs and digital health companies for CNS therapeutic development in the near future?
  • Can the development of CNS specific clinical trials help accelerate potential drugs into the hands of the patients?
  • Panelists, what is the likelihood that we see a resurgence of pharmaceutical companies into the CNS space as their mainstream efforts in the next 5 years?

Mads Dalsgaard, SVP, Head of Experimental Medicine & Clinical Development, Lundbeck

Ken Kramer, AVP, Global Therapeutic Area Lead, Neuroscience, AbbVie

Anish Shindore, Head of Neurotech & Open Innovation, Biogen

12:35pm ET

Lunch

Day 1 of The CNS Leaders Forum includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Digital Solutions Showcase

2pm ET

Presentation: Using Linguistic Biomarkers to Identify and Monitor Cognitive Wellness

  • A look into utilizing voice tech to help Identify and Monitor CNS disorders
  • An understanding of which biomarkers are identified and how these relate to cognitive disorders
  • What is the future for vocal biomarkers in CNS patient care?

Liam Kaufman, Co-Founder & CEO, Winterlight Labs

2:25pm ET

Wellness Break

2:30pm ET

Presentation: How Digital Health and Digital Therapeutics are Leading the Charge Against CNS Disorders

  • How have digital solutions enabled a resurgence of CNS Treatments available for patients?
  • Are digital therapeutics enough or is a pairing with a traditional drug also required?
  • What areas have we seen success using DTx for CNS treatments and will we ever see a digital ‘Cure’?

Eddie Martucci, Co-Founder & CEO, Akili Interactive

2:55pm ET

Wellness Break

3pm ET

Panel Discussion: The Impact of Digital Interventions for CNS Patient Intervention and Treatment

  • What impact have digital health solutions had on the prevention and treatment of CNS diseases?
  • How can digital solutions help increase efficacy of current and future traditional CNS therapies?
  • Where have we seen success using digital solutions in treating more severe CNS disorders such as alzheimers, dementia and parkinsons?
  • Are digital solutions optimised for diagnosis or prevention and what are the current efforts for a digital cure?
  • Is the future of CNS patient treatment digital, traditional drugs or a combination of both?

Kim Braden-Kristensen, Co-Founder & CEO, Brain+

Ciara Clancy, Founder & CEO, Beats Medical

Kate Rosenbluth, Co-Founder & CSO, Cala Health

Brent Vaughan, Chief Executive Officer, Cognito Therapeutics

3:45pm ET

Wellness Break

3:50pm ET

Presentation: Ensuring Early Diagnosis of CNS disorders from Healthcare Professionals

  • A look at Alzheimer’s Disease International’s work helping those affected by CNS Disorders
  • How can we educate Healthcare providers, Patients and Patient Carers to ensure they are best equipped to tackle CNS Diseases?
  • What needs to be done to ensure quality care for CNS patients?

Paola Barbarino, Chief Executive Officer, Alzheimer’s Disease International

4:15pm ET

Wellness Break

4:20pm ET

Panel Discussion: How can the CNS Industry work Together for Future Patient Success?

  • What are the next big steps required to advance effective therapies into the hands of the patients?
  • Where should our efforts be focused to help further the industry?
  • How can we demonstrate value in CNS therapies to investors, payers and healthcare providers?
  • What is the biggest challenge holding back the industry right now?
  • What does the future of Patient care for CNS look like?

Fransisco Jurado, Chief Scientific Officer, Neuraxpharm

Paola Barbarino, Chief Executive Officer, Alzheimer’s Disease International

Rebecca Howard, Chief Executive Officer & Research Director, Howard Brain Sciences Foundation

Adam Koppel, Managing Director, Bain Capital

5:05pm ET

Chair’s Closing Remarks

Magdalene Moran, President & Chief Scientific Officer, Caraway Therapeutics

5:10pm ET

End of CNS Leaders Forum Day 1

Download the Agenda

Conference Day 2

  • Wednesday, June 16th
Wednesday, June 16th
8:00am ET

Conference Platform Opens

9:00am ET

Chair’s Opening Remarks

Magdalene Moran, President & Chief Scientific Officer, Caraway Therapeutics

9:05am ET

Keynote Presentation: How Ground-Level Research is Tackling CNS Disorders

  • An insight into the current foundational work being carried out to within central nervous system disorders
  • What hurdles prevent us from exploring prevention, diagnosis and treatment of CNS Disease?
  • Where is the ceiling for CNS treatment for patients?

Speaker to be Announced

9:30am ET

Wellness Break

9:35am ET

Panel Discussion: What are Investors Looking for when Investing in CNS Therapeutics Areas? 

  • Are Investors actively looking into the CNS area for investment opportunities? 
  • What is preventing investors from pulling the trigger on CNS therapeutic investments?
  • What evidence do investors need to see to prompt investment?
  • Are digital solutions more likely to see investment than traditional therapies?
  • Do investors believe we will see success in the near future for CNS therapeutics?

Lana Ghanem, Managing Director, Hikma Ventures

Pavan Choksi, Venture Partner, Arkitekt Ventures

Laurence Barker, Partner & Chief Business Officer, Dementia Discovery Fund

Stacie Weninger, President, F-Prime Capital

10:20am ET

Wellness Break

Industry Insights

10:25am ET

Presentation: An Insight into Caraway Therapeutics

  • A deep dive into Caraway’s current therapeutics efforts for treating CNS Disorders
  • How are Caraway Therapeutics ensuring success in the CNS field?
  • What’s next for Caraway Therapeutics?

Magdalene Moran, President & Chief Scientific Officer, Caraway Therapeutics

10:50am ET

Wellness Break

10:55am ET

Presentation: Deep Dive Case Study into Neuraxpharm

  • An insight into how Neuraxpharm are developing new CNS therapeutics while also enhancing current therapies already in the market 
  • How are Neuraxpharm ensuring success utilizing this business model?
  • A deep-dive into the future of Neuraxpharm

Fransisco Jurado, Chief Scientific Officer, Neuraxpharm

11:20am ET

Wellness Break

11:25am ET

Presentation: Treating Alzheimers using Non-Invasive Digital Neuro-stimulation – A Case Study

  • An insight into Cognito’s digital tool for treating Alzheimers
  • How does Cognito’s breakthrough device help treat Alzheimers?
  • What can we expect next from Cognito Therapeutics?

Brent Vaughan, Chief Executive Officer, Cognito Therapeutics

11:50am ET

Wellness Break

11:55am ET

Panel Discussion: How can we Improve Frontline Care for CNS Patients?

  • How can we educate patients and care-givers to ensure they are familiar with potential therapies?
  • How can we help re-educate health care professionals to aid in early diagnostics for CNS disorders?
  • What interventions can we put into place to help assist patients further?
  • Are we currently serving patients with CNS disorders enough?

Donna Walsh, Executive Director, European Federation of Neurological Associations

Sabrina Paganoni, Co-Director, MGH Neurological Clinical Research Institute

12:40pm ET

Chair’s Closing Remarks

Magdalene Moran, President & Chief Scientific Officer, Caraway Therapeutics

12:45pm ET

Close of the CNS Leaders Forum

Download the Agenda